Clinical Trial

Mechanisms of Atrial Pathoelectrophysiology in HCM

Study acronym: MAP HCM
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to learn why atrial fibrillation (AF), a type of irregular heartbeat, happens more often and is harder to treat in people with hypertrophic cardiomyopathy (HCM). HCM is an inherited condition where the heart muscle is thicker than usual. Researchers will study electrical signals from the heart and advanced heart imaging. By doing this, they hope to better understand how AF behaves in people with HCM and why treatments may not work as well for them. The information from this study may help improve future treatments for people who have both HCM and AF.
Protocol Amendment History 1 change
critical Primary endpoint(s) modified 2026-04-07
Trial Details
NCT Number NCT07454135
Lead Sponsor Guy's and St Thomas' NHS Foundation Trust
Collaborators: King's College London
Conditions Hypertrophic Cardiomyopathy (HCM), Atrial Fibrillation (AF)
Enrollment 40 participants
Start Date 2026-03-08
Primary Completion 2027-09-30 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-06